Medigus: Leading Life Science and Pharmaceutical Entrepreneur Mori Arkin to Join ScoutCam’s Board of Directors
February 16 2021 - 10:05AM
Medigus Ltd. (Nasdaq: MDGS), a technology company engaged in
advanced medical solutions and innovative internet technologies,
announced today that ScoutCam Inc. (OTCQB: SCTC), Medigus’
subsidiary and a leading developer and manufacturer of customized
micro visual solutions and supplementary technologies, that Mr.
Mori Arkin has been appointed to its board of directors.
On May 18, 2020, Mr. Arkin invested $2 million
in ScoutCam through his investment company, Arkin Holdings, and, in
connection with the investment, appointed Dr. Irit Yaniv as a
ScoutCam’s board member and representative of Arkin Holdings. After
carefully observing ScoutCam’s positive momentum over the past
several months, including in his capacity as a special advisor to
ScoutCam on matters related to intellectual property, Mr. Arkin
decided to replace Dr. Yaniv and represent Arkin Holdings on the
board himself.
Prof. Benad Goldwasser, the Executive Chairman
of Scoutcam’s board, expressed his gratitude to Dr. Yaniv for her
contribution. At the same time, he thanked Mr. Arkin for taking
this momentous step of assuming an active role on the board of
ScoutCam and thereby demonstrating his belief in ScoutCam and its
growing potential.
Mr. Arkin said “My decision to formally join the
ScoutCam board reflects my growing belief in this company and its
potential, including beyond visualization solutions for the medical
industry. ScoutCam, in my mind, has only begun to tap into its vast
potential, and that the applications of its technology are
limitless, whether in the fields of maintenance and predictive
maintenance, a critical pillar of Industry 4.0, aviation and
defense, and more. I am excited to take a more active role on the
company’s leadership team to help realize this impressive
potential.”
Founder and Chairman of Arkin Holdings, Moshe
“Mori” Arkin, is one of Israel’s most successful life sciences and
pharmaceutical entrepreneurs. A renowned industrialist and generic
drug specialist, he founded Arkin Holdings, which owns, among other
investments, a healthcare portfolio of $1 billion through various
investment arms, with holdings in some 20 companies, many of them
Israeli companies, developing pharmaceutical drugs and medical
equipment, such as UroGen Pharma, Keros Therapeutics and Novolog.
Mori previously grew Agis into a leading pharmaceutical company and
sold it to Perrigo in 2005 for $818 million.
About Medigus
Medigus is traded on the Nasdaq Capital Market.
To learn more about the company’s advanced technology, please
visit www.medigus.com.
Cautionary Note Regarding Forward Looking
Statements
This press release may contain statements that
are “Forward-Looking Statements,” which are based upon the current
estimates, assumptions and expectations of Medigus’ management and
its knowledge of the relevant market. The company has tried, where
possible, to identify such information and statements by using
words such as “anticipate,” “believe,” “envision,” “estimate,”
“expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,”
“potential,” “will,” “would,” “could,” “should,” “continue,”
“contemplate” and other similar expressions and derivations thereof
in connection with any discussion of future events, trends or
prospects or future operating or financial performance, although
not all forward-looking statements contain these identifying words.
For example, Medigus uses forward looking statements when
describing ScoutCam’s ability to maximize the economic potential
and monetize the technology covered in the press release and the
material and positive effect Mr. Arkin’s appointment will have on
ScoutCam’s business and operations. These forward-looking
statements represent Medigus’ expectations or beliefs concerning
future events, and it is possible that the results described in
this press release will not be achieved, due to inter alia the
spread of COVID-19 as well as the restriction deriving therefrom
and difficulties arising from the development and manufacture of
wireless charging products. Nothing in the description herein
should be understood or construed as an announcement of completed
products or an existing proof of concept. By their nature,
Forward-Looking Statements involve known and unknown risks,
uncertainties and other factors which may cause future results of
the Medigus’ activity to differ significantly from the content and
implications of such statements. Other risk factors affecting
Medigus are discussed in detail in the Medigus’ filings with the
Securities and Exchange Commission. Forward-Looking Statements are
pertinent only as of the date on which they are made, and Medigus
undertakes no obligation to update or revise any Forward-Looking
Statements, whether as a result of new information, future
developments or otherwise. Neither Medigus nor its shareholders,
officers and employees, shall be liable for any action and the
results of any action taken by any person based on the information
contained herein, including without limitation the purchase or sale
of Medigus’ securities. Nothing in this press release should be
deemed to be medical or other advice of any kind.
Contact (for media only)Oz Adler Chief
Financial Officer +972-8-6466-880 ir@medigus.com
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Feb 2024 to Mar 2024
Medigus (NASDAQ:MDGS)
Historical Stock Chart
From Mar 2023 to Mar 2024